Why Investors Are Voting Against VIVUS

In this video, health-care analyst David Williamson discusses the sector's three biggest losers today, including VIVUS after posting poor third-quarter results. Watch and find out what investors should take away from these disappointing results and catch up on the day's other big movers.

The ravages of America's obesity epidemic pose a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand-new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.